| scholarly article | Q13442814 |
| P50 | author | Mong Cho | Q95971785 |
| P2093 | author name string | Seung Kew Yoon | |
| Jong Young Choi | |||
| Dong Joon Kim | |||
| Hyun Young Woo | |||
| Byung Ik Kim | |||
| Kwang Hyub Han | |||
| Seung Woon Paik | |||
| Chun Kyon Lee | |||
| Dong Jin Suh | |||
| Jae Seok Hwang | |||
| Soon Ho Um | |||
| Heon Ju Lee | |||
| P2860 | cites work | Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. | Q54599747 |
| Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results | Q57791894 | ||
| Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver | Q67576524 | ||
| Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation | Q71869661 | ||
| Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B | Q73308069 | ||
| A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts | Q28139627 | ||
| A model to predict survival in patients with end-stage liver disease | Q28199900 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | Q28212394 | ||
| Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list | Q30440211 | ||
| Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group | Q31405858 | ||
| Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis | Q31431612 | ||
| A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. | Q31921588 | ||
| Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil | Q33233245 | ||
| Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine | Q33963063 | ||
| Chronic hepatitis B. | Q34002160 | ||
| Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures | Q34302587 | ||
| Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 | ||
| Molecular virology and the development of resistant mutants: implications for therapy | Q36231804 | ||
| A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update | Q36537686 | ||
| Hepatitis B virus. The major etiology of hepatocellular carcinoma | Q39199064 | ||
| Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection | Q41604155 | ||
| Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection | Q41757004 | ||
| Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy | Q44116666 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. | Q44329201 | ||
| Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients | Q44675031 | ||
| Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus | Q44709441 | ||
| Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. | Q44709445 | ||
| Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. | Q45023133 | ||
| Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy | Q45414035 | ||
| Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis | Q45441454 | ||
| Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus | Q45787408 | ||
| Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis | Q46712921 | ||
| Virologic response and resistance to adefovir in patients with chronic hepatitis B. | Q46842950 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | Hepatitis B virus | Q6844 |
| liver cirrhosis | Q147778 | ||
| P304 | page(s) | 168-176 | |
| P577 | publication date | 2014-06-30 | |
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus | |
| P478 | volume | 20 |
| Q64093388 | Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study | cites work | P2860 |
Search more.